Literature DB >> 24554250

Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation.

Naoko Sasaki1, Yasuo Okumura, Ichiro Watanabe, Hiroaki Mano, Koichi Nagashima, Kazumasa Sonoda, Rikitake Kogawa, Kimie Ohkubo, Toshiko Nakai, Atsushi Hirayama.   

Abstract

PURPOSE: Left atrial (LA) remodeling associated with atrial fibrillation (AF) is known to be related to inflammation and collagen turnover. We investigated the changes in the biomarkers of inflammation and collagen turnover in relation to LA reverse remodeling during the 1st year after AF ablation.
METHODS: Biomarkers of inflammation [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)] and collagen turnover [matrix metalloproteinase-2 (MMP-2), tissue inhibitor of MMP-2 (TIMP-2), transforming growth factor beta 1 (TGF-β1)], as well as asymmetric dimethylarginine (ADMA) and adiponectin levels were measured, and echocardiographic measurements were obtained before and 3, 6, and 12 months after ablation in 60 AF patients (49 males; age, 57.6 ± 10.9 years).
RESULTS: During a 12.1 (11.5-12.9)-month follow-up period, AF recurred in 29 patients (48 %). Neither the LA volume (LAV) nor the left ventricular ejection fraction (LVEF) changed significantly during the 1st year in this group, but the LAV decreased significantly, and the LVEF increased significantly in the nonrecurrence group. The hs-CRP and IL-6 decreased after ablation but returned near to baseline levels in both groups by 12 months. The MMP-2 remained increased during the 1st year in both groups, whereas the TIMP-2 increased markedly in the nonrecurrence group but did not change substantially in the recurrence group. The TGF-β1 increased in both groups, but the change was less pronounced in the recurrence group. The ADMA and adiponectin levels did not change substantially in either group.
CONCLUSIONS: Despite reverse remodeling, the inflammation and collagen turnover biomarker levels are quite progressive during the 1st year after ablation and may explain the late AF recurrence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554250     DOI: 10.1007/s10840-013-9867-6

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  31 in total

1.  Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation.

Authors:  Takumi Yamada; Yoshimasa Murakami; Taro Okada; Naoki Yoshida; Junji Toyama; Yukihiko Yoshida; Naoya Tsuboi; Yasuya Inden; Makoto Hirai; Toyoaki Murohara
Journal:  Europace       Date:  2007-08-01       Impact factor: 5.214

2.  Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence.

Authors:  Yasuo Okumura; Ichiro Watanabe; Toshiko Nakai; Kimie Ohkubo; Tatsuya Kofune; Masayoshi Kofune; Koichi Nagashima; Hiroaki Mano; Kazumasa Sonoda; Yuji Kasamaki; Atsushi Hirayama
Journal:  J Cardiovasc Electrophysiol       Date:  2011-04-13

3.  Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans.

Authors:  Norbert Stefan; Barbora Vozarova; Tohru Funahashi; Yuji Matsuzawa; Christian Weyer; Robert S Lindsay; Jack F Youngren; Peter J Havel; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

4.  Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Andrea Natale; Douglas Packer; Allan Skanes; Federico Ambrogi; Elia Biganzoli
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-07

Review 5.  Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?

Authors:  E E Creemers; J P Cleutjens; J F Smits; M J Daemen
Journal:  Circ Res       Date:  2001-08-03       Impact factor: 17.367

6.  The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.

Authors:  Rhidian J Shelton; Andrew L Clark; Kevin Goode; Alan S Rigby; John G F Cleland
Journal:  Eur Heart J       Date:  2006-09-04       Impact factor: 29.983

Review 7.  Inflammation in the genesis and perpetuation of atrial fibrillation.

Authors:  Mads D M Engelmann; Jesper Hastrup Svendsen
Journal:  Eur Heart J       Date:  2005-06-23       Impact factor: 29.983

8.  Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation.

Authors:  Li Yang; Qu Xiufen; Sun Shuqin; Yu Yang; Song Ying; Yu Yanwei; Feng Wei; Yin Dechun
Journal:  J Interv Card Electrophysiol       Date:  2011-05-19       Impact factor: 1.900

9.  Histopathological substrate for chronic atrial fibrillation in humans.

Authors:  Bich Lien Nguyen; Michael C Fishbein; Lan S Chen; Peng-Sheng Chen; Saqib Masroor
Journal:  Heart Rhythm       Date:  2009-01-16       Impact factor: 6.343

10.  Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction.

Authors:  Jens J Kaden; Carl-Erik Dempfle; Tim Sueselbeck; Martina Brueckmann; Tudor C Poerner; Dariusch Haghi; Karl K Haase; Martin Borggrefe
Journal:  Cardiology       Date:  2003       Impact factor: 1.869

View more
  10 in total

Review 1.  Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Falco Kosich; Katja Schumacher; Tatjana Potpara; Gregory Y Lip; Gerhard Hindricks; Jelena Kornej
Journal:  Clin Cardiol       Date:  2019-01-14       Impact factor: 2.882

Review 2.  Atrial fibrillation and heart failure: cause or effect?

Authors:  Christina Luong; Marion E Barnes; Teresa S M Tsang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 3.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

4.  Morphine but not fentanyl and methadone affects mitochondrial membrane potential by inducing nitric oxide release in glioma cells.

Authors:  D Mastronicola; E Arcuri; M Arese; A Bacchi; S Mercadante; P Cardelli; G Citro; P Sarti
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

5.  Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial).

Authors:  Pavel Osmancik; Štěpán Havránek; Veronika Bulková; Jan Chovančík; Tomáš Roubíček; Dalibor Heřman; Zuzana Čarná; Vladimír Tuka; Martin Matoulek; Martin Fiala; Otakar Jiravský; Sylvie Stregl-Hruskova; Adam Latiňák; Jiřina Kotryová; Jiří Jarkovský
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

6.  Renal function after repeat catheter ablation for long-standing persistent atrial fibrillation : Low CHA2DS2-VASc score and sinus rhythm predict improved renal function.

Authors:  Q Wang; X-D Zhang; X Liu; Y-Q Yang
Journal:  Herz       Date:  2016-01-25       Impact factor: 1.443

7.  Clinical implications of serum adiponectin on progression of atrial fibrillation.

Authors:  Naoko Yamaguchi; Yasuo Okumura; Ichiro Watanabe; Koichi Nagashima; Keiko Takahashi; Kazuki Iso; Ryuta Watanabe; Masaru Arai; Sayaka Kurokawa; Kimie Ohkubo; Toshiko Nakai; Atsushi Hirayama
Journal:  J Arrhythm       Date:  2017-09-13

8.  Increased serum lysyl oxidase-like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation.

Authors:  Yingming Zhao; Kangting Tang; Xu Tianbao; Junhong Wang; Jin Yang; Dianfu Li
Journal:  Biosci Rep       Date:  2017-11-21       Impact factor: 3.840

9.  Effect of epicardial fat and metabolic syndrome on reverse atrial remodeling after ablation for atrial fibrillation.

Authors:  Koyuru Monno; Yasuo Okumura; Yuki Saito; Yoshihiro Aizawa; Koichi Nagashima; Masaru Arai; Ryuta Watanabe; Yuji Wakamatsu; Naoto Otsuka; Shunichi Yoda; Takafumi Hiro; Ichiro Watanabe; Atsushi Hirayama
Journal:  J Arrhythm       Date:  2018-10-13

10.  Advanced glycation end products predict long-term outcome of catheter ablation in paroxysmal atrial fibrillation.

Authors:  Allan Bohm; Lubos Urban; Lubomira Tothova; Ljuba Bacharova; Peter Musil; Jan Kyselovic; Peter Michalek; Tomas Uher; Branislav Bezak; Peter Olejnik; Robert Hatala
Journal:  J Interv Card Electrophysiol       Date:  2021-03-10       Impact factor: 1.900

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.